Expert wants anti-cancer drug subsidised

PUBLISHED : Wednesday, 14 May, 2008, 12:00am
UPDATED : Wednesday, 14 May, 2008, 12:00am
 

A University of Hong Kong cancer expert wants a newly registered anti-breast cancer drug put on the Hospital Authority's formulary. Daniel Chua Tsin-tien, associate professor of HKU's clinical oncology department, said that tests using the drug, lapatinib, combined with capecitabine, showed an 88 per cent chance of patients with last-stage HER2 breast cancer controlling the disease. There was a 35 per cent chance tumours would shrink in size by more than half.

Share

Send to a friend

To forward this article using your default email client (e.g. Outlook), click here.

Enter multiple addresses separated by commas(,)

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Related topics